Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna Stock Surges 260% YTD on Coronavirus Vaccine Progress

by Zacks Equity Research

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. The vaccine is currently in phase III study.

Zacks Equity Research

AstraZeneca Begins Coronavirus Antibody Combo Phase I Study

by Zacks Equity Research

AstraZeneca's (AZN) AZD7442 is a combination of two coronavirus-neutralizing monoclonal antibodies, AZD8895 and AZD1061.

Sweta Killa headshot

5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks

by Sweta Killa

While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.

Zacks Equity Research

Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study

by Zacks Equity Research

Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.

Zacks Equity Research

AstraZeneca Coronavirus Vaccine May Get FDA's Emergency Tag

by Zacks Equity Research

AstraZeneca's (AZN)/Oxford's AZD1222 is in phase II/III study in the UK, Brazil and South Africa with a late-stage study due to start soon in the United States with 30,000 participants.

Zacks Equity Research

Regeneron Gains on Coronavirus Treatment Development Efforts

by Zacks Equity Research

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.

Zacks Equity Research

Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa

by Zacks Equity Research

Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.

Zacks Equity Research

AstraZeneca (AZN) to Supply Coronavirus Vaccine in Europe

by Zacks Equity Research

AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved.

Zacks Equity Research

Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government

by Zacks Equity Research

Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.

Sweta Jaiswal, FRM headshot

Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine

by Sweta Jaiswal, FRM

Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.